Chrissy Buteas, President and CEO of the HealthCare Institute of New Jersey, has commented on the Senate Legislative Oversight Committee's hearing titled "How artificial intelligence (AI) is defined and the AI landscape in New Jersey." The hearing focused on the state's position in leading medical innovation through AI.
Buteas stated, "New Jersey and our state’s innovation ecosystem are at the forefront of and exceedingly well-positioned to continue leading the world in medical innovation. Harnessing the promise of artificial intelligence (AI) in our home state will strengthen our ability to find new treatments, cures, and diagnostic tools that will save lives in New Jersey, the United States and around the world."
She highlighted that while AI's potential is being recognized globally, life sciences and the FDA have been developing AI-driven technologies for nearly three decades. These advancements adhere to HIPAA standards and state privacy rules, transforming patient care ethically.
Buteas elaborated on how AI has improved research and development within life sciences by enhancing surgical procedures like robotic-assisted surgery, expediting medicine discovery through data analysis, improving clinical trial recruitment, and advancing smart manufacturing processes.
She emphasized that these advancements were made possible by a rigorous yet predictable regulatory system enforced by the FDA. Buteas called for a public-private partnership involving various sectors to fully harness AI's potential. She concluded with optimism about working with policymakers to continue saving lives globally through innovative treatments developed in New Jersey.
